DYRK1B Antibody

What is DYRK1B and why is it important in research?

DYRK1B, also known as MIRK (Minibrain related kinase), is a member of the DYRK/minibrain family of serine/threonine kinases that mediate the transition from growth to differentiation in various organisms. Despite promoting proliferative quiescence, DYRK1B is paradoxically overexpressed or amplified in many hyperproliferative malignancies, including ovarian and pancreatic cancers. Recent studies have identified DYRK1B as a key regulator of both cancer cell-intrinsic processes and the tumor microenvironment, making it an attractive target for therapeutic development in therapy-resistant cancers . DYRK1B functions as a transcriptional coactivator that can be activated by co-expressed MKK3, a MAP kinase that also activates p38 MAP kinase .

What are the primary applications for DYRK1B antibodies in research?

DYRK1B antibodies are essential tools for various experimental applications including:

• Western blotting to detect protein expression in tissues and cell lines

• Immunohistochemistry and immunofluorescence for localization studies

• Protein-protein interaction studies via immunoprecipitation

• Validation of genetic knockdown experiments

• Monitoring DYRK1B expression changes under various conditions (serum starvation, cell density, pharmacological treatments)

• Investigating DYRK1B's role in disease models including cancer and inflammatory conditions

How can I distinguish between DYRK1A and DYRK1B using antibodies?

Despite sharing over 85% sequence identity in their catalytic domains, DYRK1A and DYRK1B can be distinguished using paralog-specific antibodies. When selecting antibodies, researchers should prioritize:

• Antibodies raised against regions with lower sequence homology

• Validation using cells with confirmed knockdown of either DYRK1A or DYRK1B

• Confirmation with secondary methods (e.g., mass spectrometry)

• Control experiments with recombinant DYRK1A and DYRK1B proteins

Recent studies have demonstrated that knockdown of DYRK1B but not DYRK1A affects extracellular vesicle production, highlighting the importance of paralog-specific detection .

What are the optimal conditions for Western blot detection of DYRK1B?

For optimal Western blot detection of DYRK1B:

• Use antibody dilutions between 1:1000-1:10000 as recommended for most commercial antibodies

• Expected molecular weight: The primary band should appear at approximately 57-69 kDa depending on the isoform

• Include positive controls such as mouse testis tissue, HeLa cells, human colon tissue, or human heart tissue where DYRK1B expression has been confirmed

• For extraction, use buffers containing phosphatase inhibitors to preserve phosphorylation status

• Include SDS-PAGE separation under reducing conditions

• For detection of phosphorylated DYRK1B (particularly tyrosine phosphorylation), specific anti-phospho antibodies may be required

How should I design DYRK1B knockdown validation experiments?

When validating DYRK1B knockdown experiments:

• siRNA design considerations:

  • Target sequences unique to DYRK1B to avoid off-target effects

  • Include both DYRK1A and non-targeting siRNA controls

• Validation methodology:

  • Confirm knockdown efficiency by Western blot (protein level)

  • Validate at the mRNA level using qRT-PCR

  • Assess functional outcomes such as changes in cell phenotype

• Expected results:

  • A reduction in target protein band intensity (typically 60-80% reduction is considered successful)

  • Changes in downstream effects (e.g., 36.6% reduction in extracellular vesicle number has been observed with DYRK1B knockdown but not with DYRK1A knockdown)

What immunofluorescence protocols work effectively for DYRK1B detection?

For effective immunofluorescence detection of DYRK1B:

• Cell preparation:

  • Fix cells with 4% paraformaldehyde

  • Permeabilize with 0.1-0.2% Triton X-100

• Antibody incubation:

  • Block with 3-5% BSA or normal serum

  • Use primary DYRK1B antibody at appropriate dilution (typically 1:100-1:500 for immunofluorescence)

  • Include counterstains for contextual localization (e.g., DAPI for nuclei, phalloidin for actin)

• Controls and analysis:

  • Include DYRK1B knockdown controls

  • Analyze both distribution patterns and fluorescence intensity

  • Quantify using parameters such as total area of protein expression and fluorescence intensity per pixel

When analyzing DYRK1B's relationship with other proteins (e.g., CD63), researchers have observed distinctive changes in punctate distribution patterns following DYRK1B knockdown, with CD63 showing perinuclear accumulation rather than distributed punctae .

How can DYRK1B antibodies be used to study its role in the tumor microenvironment?

DYRK1B antibodies are instrumental in studying its complex role in the tumor microenvironment:

• Tissue microarray analysis:

  • Use immunohistochemistry on patient-derived samples

  • Correlate DYRK1B expression with immune cell infiltration and tumor progression

• Co-culture experimental design:

  • Implement cell-specific markers alongside DYRK1B staining

  • Compare DYRK1B expression in cancer cells versus tumor-associated macrophages

• Methodology for studying macrophage interactions:

  • Co-staining for DYRK1B and macrophage markers

  • Analysis of phagocytosis following DYRK1B inhibition or knockdown

  • Evaluation of CD24 ("don't eat me" signal) regulation by DYRK1B

Recent research has revealed that DYRK1B expression in pancreatic cancer cells influences tumor-associated macrophage activity. Genetic ablation or pharmacological inhibition of DYRK1B attracts tumoricidal macrophages and downregulates CD24, enhancing tumor cell phagocytosis .

What controls should be implemented when using DYRK1B antibodies to assess the efficacy of DYRK1B inhibitors?

When evaluating DYRK1B inhibitors using antibodies:

• Control panel:

  • Positive control: Untreated cells with confirmed DYRK1B expression

  • Negative control: DYRK1B knockdown cells

  • Specificity control: DYRK1A knockdown cells

  • Treatment control: Cells treated with established inhibitors (e.g., AZ191)

• Validation approaches:

  • Combine antibody-based detection with functional assays

  • Monitor downstream effects (e.g., macrophage activation, CD24 regulation)

  • Assess phosphorylation status of known DYRK1B substrates

  • Use thermal shift assays to confirm target engagement

• Data interpretation:

  • IC50 determination from dose-response curves

  • Comparative analysis between DYRK1A and DYRK1B inhibition

Research has demonstrated that selective DYRK1B inhibitors like AZ191 show greater potency against DYRK1B (IC50 = 66 nM) compared to DYRK1A (IC50 = 188 nM) in kinase activity assays .

How can DYRK1B antibodies help characterize DYRK1B's role in extracellular vesicle regulation?

DYRK1B has been identified as a novel regulator of small extracellular vesicles:

• Experimental approach:

  • Use immunofluorescence to track co-localization with EV markers

  • Implement nanoscale flow cytometry following DYRK1B inhibition/knockdown

  • Analyze CD63 distribution patterns using DYRK1B antibodies

• Observed effects of DYRK1B knockdown:

  • 36.6% reduction in EV number

  • Altered CD63 distribution from punctate to perinuclear accumulation

  • Changes in CD63 protein levels detectable by Western blot

• Analytical methods:

  • Quantitative image analysis of CD63 area and intensity

  • Flow cytometric quantification of EVs in conditioned media

  • Western blot analysis of EV marker proteins

These approaches have demonstrated that DYRK1B knockdown significantly alters CD63 distribution patterns and reduces extracellular vesicle production, suggesting an important role for DYRK1B in EV biogenesis or release .

How can I address cross-reactivity issues when using DYRK1B antibodies?

To minimize cross-reactivity issues:

• Antibody selection criteria:

  • Choose antibodies raised against unique epitopes

  • Prioritize antibodies validated against DYRK1A

  • Consider monoclonal antibodies for higher specificity

• Validation approach:

  • Test antibodies on samples with DYRK1A and DYRK1B knockdown

  • Include recombinant proteins as positive controls

  • Perform peptide competition assays

• Technical adjustments:

  • Optimize antibody concentration to minimize background

  • Increase washing steps

  • Pre-absorb antibodies if necessary

When studying DYRK1B-specific functions, researchers have successfully verified specificity by showing that DYRK1A knockdown does not reproduce the same phenotypic effects as DYRK1B knockdown .

What strategies can help detect DYRK1B expression changes under different cellular conditions?

DYRK1B expression varies under different cellular conditions:

• Experimental conditions to consider:

  • Serum deprivation (upregulates DYRK1B but not DYRK1A)

  • Cell density (increased density upregulates DYRK1B)

  • mTOR inhibition

  • Aurora kinase inhibition

• Detection approach:

  • Monitor both protein levels (Western blot) and mRNA levels (qRT-PCR)

  • Track changes over multiple time points

  • Combine with functional assays

• Data analysis:

  • Apply linear regression models to analyze time-dependent changes

  • Compare DYRK1B vs. DYRK1A expression patterns

  • Correlate with cell cycle phase

Research has shown that prolonged cultivation of A549 cells in the presence of serum results in higher DYRK1B protein levels than serum depletion after 144 hours of treatment, while DYRK1A protein levels remain relatively constant .

How can antibodies help assess DYRK1B's phosphorylation status and conformational stability?

DYRK1B's activity depends on its phosphorylation status:

• Key phosphorylation sites:

  • Tyrosine autophosphorylation is essential for DYRK1B activation

  • Mutant DYRK1B proteins (H90P, R102C) show underphosphorylation on tyrosine

• Detection methods:

  • Phospho-specific antibodies

  • Mobility shift detection in Western blots

  • Combined immunoprecipitation and phospho-detection

• Conformational stability assessment:

  • HSP90 inhibitor sensitivity correlates with conformational instability

  • Co-immunoprecipitation with chaperones (CDC37)

  • Detergent solubility analysis

Research on DYRK1B mutations associated with metabolic syndrome has shown that mutant DYRK1B variants accumulate in detergent-insoluble cytoplasmic aggregates, are underphosphorylated on tyrosine, show enhanced vulnerability to HSP90 inhibitors, and display increased binding to the co-chaperone CDC37 .

How can DYRK1B antibodies be utilized in pancreatic cancer research?

DYRK1B antibodies are valuable tools in pancreatic cancer research:

• Expression analysis in tumor samples:

  • Tissue microarray studies of patient samples

  • Correlation with clinical outcomes and tumor characteristics

• Mechanistic studies:

  • Detection of DYRK1B in both cancer cells and tumor microenvironment

  • Analysis of secretome effects on macrophage recruitment and activity

  • Evaluation of CD24 regulation by DYRK1B

• Therapeutic response assessment:

  • Monitoring DYRK1B levels following treatment

  • Correlation with treatment resistance mechanisms

Research has demonstrated that DYRK1B is mainly expressed by pancreatic epithelial cancer cells and modulates the influx and activity of tumor microenvironment-associated macrophages. Genetic ablation or pharmacological inhibition of DYRK1B attracts tumoricidal macrophages and enhances tumor cell phagocytosis by downregulating the "don't eat me" signal CD24 on cancer cells .

What role do DYRK1B antibodies play in studying inflammatory conditions?

DYRK1B antibodies help elucidate its role in inflammatory conditions:

• Experimental design for inflammatory models:

  • Detection of DYRK1B in immune cells

  • Analysis of T cell differentiation following DYRK1B inhibition

  • Assessment of FOXO1 phosphorylation status

• Observed effects in allergic contact dermatitis models:

  • Reduced ear inflammation with DYRK1B inhibition

  • Significant reduction of Th1 and Th17 cells in regional lymph nodes

  • Promotion of regulatory T cell differentiation

• Mechanistic insights:

  • DYRK1B inhibition enhances FOXO1 signaling

  • Suppression of FOXO1 Ser329 phosphorylation

  • Regulation of CD4 T cell differentiation

Studies using murine contact hypersensitivity models have shown that DYRK1B inhibition reduces inflammation by suppressing Th1/Th17 differentiation while promoting regulatory T cell development, suggesting potential for DYRK1B inhibitors as novel agents for treating allergic contact dermatitis .

How can DYRK1B antibodies contribute to understanding metabolic syndrome?

DYRK1B antibodies provide insights into metabolic syndrome mechanisms:

• Detection of mutant DYRK1B variants:

  • Analysis of H90P and R102C mutations in the DH box

  • Assessment of conformational stability and activity

• Cellular aggregation studies:

  • Detection of detergent-insoluble cytoplasmic aggregates

  • Analysis of tyrosine phosphorylation status

  • Evaluation of chaperone interactions

• Mechanistic investigations:

  • Monitoring of DYRK1B maturation by tyrosine autophosphorylation

  • Assessment of catalytic domain conformational stability

  • Analysis of protein misfolding tendencies

Research on DYRK1B mutations (H90P and R102C) associated with an autosomal-dominant form of metabolic syndrome has shown that while these mutations don't alter the specific activity of mature kinase molecules, they compromise the conformational stability of the catalytic domain, rendering the kinase susceptible to misfolding .

How might DYRK1B antibodies contribute to developing selective DYRK1B inhibitors?

DYRK1B antibodies can play a crucial role in inhibitor development:

• Target validation approaches:

  • Confirmation of DYRK1B expression in disease models

  • Validation of knockdown phenotypes that mirror inhibition

  • Assessment of drug-target engagement

• Structural insights:

  • Analysis of the distinct binding site in the hinge region of DYRK1B

  • Comparison of inhibitor effects on DYRK1A versus DYRK1B

  • Correlation of structural changes with functional outcomes

• Inhibitor screening methodologies:

  • High-throughput compound screening platforms

  • Thermal shift assays for target engagement

  • Comparative inhibition profiles between DYRK1A and DYRK1B

Recent structural analyses have identified a distinct binding site in the hinge region of DYRK1B that is pivotal for designing selective inhibitors. Experimental data shows that inhibitors like AZ191 have stronger inhibitory effects on DYRK1B (IC50 = 66 nM) compared to DYRK1A (IC50 = 188 nM) .

What emerging applications exist for DYRK1B antibodies in combination therapy research?

DYRK1B antibodies facilitate combination therapy research:

• Therapeutic combination assessment:

  • Analysis of DYRK1B inhibition with mTOR inhibitors

  • Evaluation of DYRK1B inhibition with conventional chemotherapy

  • Investigation of immune checkpoint inhibitor combinations

• Response monitoring approaches:

  • Assessment of DYRK1B levels following treatment

  • Analysis of changes in tumor microenvironment composition

  • Evaluation of macrophage recruitment and activation

• Preclinical model findings:

  • Combining DYRK1B-directed therapy with mTOR inhibition and conventional chemotherapy stalls growth of established tumors

  • Significant extension of lifespan in aggressive pancreatic cancer models

  • Enhanced anti-tumor immune responses

Research in autochthonous pancreatic cancer models has demonstrated that combining DYRK1B inhibition with mTOR inhibition and conventional chemotherapy significantly extends lifespan, providing a novel and clinically translatable approach that warrants further investigation .

How can DYRK1B antibodies help elucidate differential regulation of DYRK1A and DYRK1B?

DYRK1B antibodies are essential for understanding differential regulation:

• Experimental conditions revealing differential expression:

  • Serum deprivation upregulates DYRK1B but not DYRK1A

  • Increased cell density elevates DYRK1B but not DYRK1A

  • mTOR inhibition differentially affects DYRK1B versus DYRK1A

• Regulatory pathway investigation:

  • Analysis of MST1/MST2 kinase roles in density-dependent regulation

  • Evaluation of Aurora kinase inhibition effects

  • Assessment of time-dependent expression changes

• Cancer context relevance:

  • DYRK1B is overexpressed in various solid tumors while DYRK1A is not

  • Different regulatory mechanisms suggest distinct functional roles

  • Therapeutic targeting may benefit from paralog-specific approaches